Nothing Special   »   [go: up one dir, main page]

SI2668209T1 - Protitelesa, selektivna za celice, ki predstavljajo egfr pri visoki gostoti - Google Patents

Protitelesa, selektivna za celice, ki predstavljajo egfr pri visoki gostoti

Info

Publication number
SI2668209T1
SI2668209T1 SI201231901T SI201231901T SI2668209T1 SI 2668209 T1 SI2668209 T1 SI 2668209T1 SI 201231901 T SI201231901 T SI 201231901T SI 201231901 T SI201231901 T SI 201231901T SI 2668209 T1 SI2668209 T1 SI 2668209T1
Authority
SI
Slovenia
Prior art keywords
high density
cells presenting
antibodies selective
egfr
presenting egfr
Prior art date
Application number
SI201231901T
Other languages
English (en)
Inventor
Ilia Alexandre Tikhomirov
Maria L. Jaramillo
Maureen D. O'connor-Mccourt
Traian Sulea
Renald Gilbert
Bruno Gaillet
Jason Baardsnes
Myriam Banville
Suzanne Grothe
Original Assignee
Gilead Sciences, Inc.
National Research Council Of Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences, Inc., National Research Council Of Canada filed Critical Gilead Sciences, Inc.
Publication of SI2668209T1 publication Critical patent/SI2668209T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SI201231901T 2011-01-24 2012-01-20 Protitelesa, selektivna za celice, ki predstavljajo egfr pri visoki gostoti SI2668209T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161435510P 2011-01-24 2011-01-24
EP12738907.0A EP2668209B8 (en) 2011-01-24 2012-01-20 Antibodies selective for cells presenting egfr at high density
PCT/CA2012/050034 WO2012100346A1 (en) 2011-01-24 2012-01-20 Antibodies selective for cells presenting egfr at high density

Publications (1)

Publication Number Publication Date
SI2668209T1 true SI2668209T1 (sl) 2021-05-31

Family

ID=46580157

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201231901T SI2668209T1 (sl) 2011-01-24 2012-01-20 Protitelesa, selektivna za celice, ki predstavljajo egfr pri visoki gostoti

Country Status (10)

Country Link
US (2) US10570211B2 (sl)
EP (1) EP2668209B8 (sl)
AU (1) AU2012211014A1 (sl)
CA (2) CA2825255C (sl)
ES (1) ES2860748T3 (sl)
PL (1) PL2668209T3 (sl)
PT (1) PT2668209T (sl)
RU (1) RU2013138177A (sl)
SI (1) SI2668209T1 (sl)
WO (1) WO2012100346A1 (sl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2825255C (en) 2011-01-24 2021-05-18 Ym Biosciences Inc. Antibodies selective for cells presenting egfr at high density
EP2925779A1 (en) * 2012-11-30 2015-10-07 Institut Pasteur Use of anti-fcyri and/or anti-fcyriia antibodies for treating arthritis, inflammation, thrombocytopenia and allergic shock
US20170319709A1 (en) 2013-07-05 2017-11-09 Formation Biologics Inc. Egfr antibody conjugates
JP2017514471A (ja) 2014-04-23 2017-06-08 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム キメラ抗原受容体（ｃａｒ）並びにその製造及び使用方法
CA2965362A1 (en) * 2014-10-31 2016-05-06 Formation Biologics Inc. Egfr antibody-based combination therapy
CN113840842A (zh) 2019-02-26 2021-12-24 詹森生物科技公司 利用双特异性抗EGFR/c-Met抗体的联合疗法和患者分层
US11879013B2 (en) 2019-05-14 2024-01-23 Janssen Biotech, Inc. Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors
WO2022241182A1 (en) * 2021-05-13 2022-11-17 Arizona Board Of Regents On Behalf Of Arizona State University A plant produced anti-egfr mabs with specific glycosylation to improve the efficacy against cancer
WO2023244276A2 (en) * 2021-10-13 2023-12-21 The Wistar Institute Of Anatomy And Biology DNA ENCODED ANTIBODIES WITH Fc MODIFICATIONS

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
CA2222231A1 (en) * 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
CN100482281C (zh) 1999-06-25 2009-04-29 基因技术股份有限公司 抗ErbB抗体-类美坦素偶联物在制备药物中的应用
US7589180B2 (en) 2001-05-11 2009-09-15 Abbott Laboratories Inc. Specific binding proteins and uses thereof
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
PL374586A1 (en) 2002-10-10 2005-10-31 Merck Patent Gmbh Bispecific anti-erb-b antibodies and their use in tumor therapy
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
IN2012DN00313A (sl) 2003-06-27 2015-05-08 Amgen Fremont Inc
US20110142822A1 (en) 2004-06-14 2011-06-16 Kussie Paul H Crystal of egfr extracellular domain and cetuximab fab fragment, and uses thereof
MX338151B (es) 2007-03-01 2016-04-05 Symphogen As Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico.
US8790649B2 (en) 2010-10-29 2014-07-29 Immunogen, Inc. EGFR-binding molecules and immunoconjugates thereof
CA2818635C (en) 2010-12-06 2021-06-15 National Reseach Council Of Canada Antibodies selective for cells presenting erbb2 at high density
CA2825255C (en) 2011-01-24 2021-05-18 Ym Biosciences Inc. Antibodies selective for cells presenting egfr at high density
RU2014121820A (ru) 2011-11-21 2015-12-27 Иммьюноджен, Инк. Способ лечения опухолей, устойчивых к анти-egfr терапиям, с помощью конъюгата антитела egfr с цитотоксическим средством
SI2968588T1 (sl) 2013-03-15 2019-05-31 AbbVie Deutschland GmbH & Co. KG Formulacije konjugatov protitelo proti-EGFR zdravilo
US20170319709A1 (en) 2013-07-05 2017-11-09 Formation Biologics Inc. Egfr antibody conjugates

Also Published As

Publication number Publication date
PL2668209T3 (pl) 2021-11-02
CA2825255C (en) 2021-05-18
US20130295086A1 (en) 2013-11-07
US10570211B2 (en) 2020-02-25
RU2013138177A (ru) 2015-03-10
EP2668209A1 (en) 2013-12-04
US12084510B2 (en) 2024-09-10
AU2012211014A1 (en) 2013-05-02
EP2668209B1 (en) 2020-12-30
EP2668209A4 (en) 2015-08-05
EP2668209B8 (en) 2021-08-11
US20200325243A1 (en) 2020-10-15
WO2012100346A1 (en) 2012-08-02
CA2825255A1 (en) 2012-08-02
CA3115406A1 (en) 2012-08-02
PT2668209T (pt) 2021-04-07
ES2860748T3 (es) 2021-10-05

Similar Documents

Publication Publication Date Title
HK1203210A1 (en) Process for cell expansion
PL2668209T3 (pl) Przeciwciało selektywne dla komórek z wysoką gęstością egfr
GB2491209B (en) Solar cell and method for producing same
GB201103955D0 (en) Antibodies
GB201112056D0 (en) Antibodies
HK1187056A1 (zh) 抗體
EP2670863A4 (en) METHOD FOR IDENTIFYING MULTIPLE EPITOPES IN CELLS
EP2681304A4 (en) NANOPIPETTES APPARATUS FOR HANDLING CELLS
EP2853590A4 (en) METHOD FOR PRODUCING ANTIGEN-SPECIFIC T LYMPHOCYTES
GB201115280D0 (en) Antibodies, uses and methods
HK1202624A1 (en) Adrenomedullin assays and methods for determining mature adrenomedullin
EP2687588A4 (en) PROCESS FOR THE PRODUCTION OF BIODIESEL
EP2686349A4 (en) METHODS OF ANTIBODY SCREENING
EP2742067A4 (en) MONOCLONAL FZD10 ANTIBODIES AND METHOD FOR THEIR USE
ZA201305116B (en) Fuel cells
ZA201400772B (en) Method for using vinasse
SG10201605531PA (en) Reconstitution methods
EP2757087A4 (en) PROCESS FOR THE PRODUCTION OF BIODIESEL
EP2706688A4 (en) SEARCH PROCESS FOR AN ADVANCED PDCCH AREA
EP2755270A4 (en) SECONDARY CELL INSPECTION METHOD
HUE058968T2 (hu) Sejtkultúra tenyésztésére szolgáló eszköz
EP2771351A4 (en) PAT-LM1 EPITOPES AND METHODS OF USE
PL2729428T3 (pl) Sposób wypalania materiałów w formie bryłek
EP2717332A4 (en) PROCESS FOR THE PRODUCTION OF SOLAR CELLS
EP2444484A4 (en) PROCESS FOR THE PREPARATION OF ANTIBODIES FROM CANCER CELLS